Takeda Provides Updates on its Hemophilia Studies at WFH 2020, Reinforcing its Commitment to Putting Patients First and Supporting Personalized Care for People with Bleeding Disorders

首圖 OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited, (「Takeda」) (TSE: 4502/NYSE:TAK) today announced a scientific update from the AHEAD real-world study investigating the …


發佈留言